Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25707280 | 1.00 | TTR (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL25177052 | 0.78 | ALDH1A1 (0.45) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL25706837 | 0.77 | CA12 (0.49) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL2302950 | 0.75 | CA12 (0.50) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL2302954 | 0.75 | CA12 (0.50) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL20223478 | 0.74 | TTR (0.43) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL30036780 | 0.74 | TTR (0.43) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL24844820 | 0.73 | CA12 (0.51) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL9331716 | 0.72 | HDAC1 (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL23174788 | 0.72 | TTR (0.47) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| EP-4476220-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4426695-A1 | KRAS G12C INHIBITORS | Frontier Medicines Corporation (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | TTR 3349/4885DPP4 3632/4885CA12 3980/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | TTR 2372/4885DPP4 3755/4885CA12 1155/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TTR 3349/4885DPP4 3632/4885CA12 3980/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TTR 3349/4885DPP4 3632/4885CA12 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.